Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Ajay K NookaNisha S JosephJonathan L KaufmanLeonard T HeffnerVikas A GuptaCharise GleasonLawrence H BoiseSagar LonialPublished in: Cancer (2019)
A better than quadrupled PFS benefit observed in cohort 1 in comparison with the previously reported benefit in the EQUULEUS trial (which led to US Food and Drug Administration approval of the DARA-POM-D combination) highlights the fact that the introduction of monoclonal antibody combination strategies and IMiDs as earlier lines of therapeutic options potentially could deliver better clinical outcomes. One-third of patients refractory to separate lines of DARA and/or POM responded when they were re-treated with a combination, and this resulted in survival benefits equivalent to those of other antimyeloma agents/combinations available for DARA-refractory patients.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- multiple myeloma
- peritoneal dialysis
- prognostic factors
- clinical trial
- risk assessment
- acute myeloid leukemia
- randomized controlled trial
- acute lymphoblastic leukemia
- patient reported outcomes
- study protocol
- phase iii
- open label
- double blind
- replacement therapy